Table 2.

Characteristics* of the patients successfully genotyped (N = 57)

Category	Parameters	Characteristics	Total [N (% or IQR)]	#P-Values
Demographics	Sex	Female	39 (68)	0.042
		Male	18 (32)
	Age at baseline	Median (IQR) years	34 (30–42)	0.921
	Marital Status	Single	12 (21)	0.663
		Married	29 (51)
		Divorced/Separated	4 (7)
		Widowed	12 (21)
	Education	None	6 (11)	0.770
		Primary	14 (25)
		Secondary	18 (32)
		Tertiary	19 (33)
	Occupation	Not Employed	15 (26)	0.338
		Employed	42 (74)
Clinical Parameters	First-line Backbone NRTI	AZT	34 (60)	0.978
		TDF	16 (28)
		bOthers	7 (12)
	First-line Second NRTI	3TC	39 (68)	0.666
		FTC	18 (32)
	First-line NNRTI	NVP	43 (75)	0.071
		EFV	14 (25)
	Time on First-line ART (Months)	ART Initiation to F1	21 (12–36)	0.217
		F1 to FC	5 (4–6)	0.086
		FC to Viral Re-suppression	5 (3–10)	0.118
Laboratory Parameters	Baseline CD4+ cells/μL	< 200	38 (67)	0.780
		200–350	17 (30)
		> 350	2 (4)
		Median (IQR)	155 (105–235)
	Baseline Viral Load (VL), copies/mL	≤100,000	36 (63)	0.774
		> 100,000	18 (32)
		Unknown	3 (5)
		Median (IQR)	43,587 (13128–176,990)
	VL at initial failure (copies/mL)	Median (IQR)	9113 (3680–49,670)	0.768
	VL at confirmatory failure (copies/mL)	Median (IQR)	16,266 (2042–4,002,513)	0.454
	HIV-1 Subtype	G	25 (44)	0.261 Grouped as G, CRF02_AG and Others
		CRF02_AG	23 (40)
		A	3 (5)
		CRF06_cpx	3 (5)
		J	1 (2)
		C	1 (2)
		Recombinant of A1, G	1 (2)

^aDemographic characteristics of those successfully genotyped were not significantly different from those not genotyped; F₁ First VL ≥ 1000 cp/mL; F_C Second VL ≥ 1000 cp/mL. ^#P-value is for difference in patient characteristic and drug resistance. IQR Interquartile range. ^bOthers = Backbone NRTI was switched